Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited
- 1 January 2019
- journal article
- research article
- Published by Elsevier BV in Genetics in Medicine
- Vol. 21 (1), 152-160
- https://doi.org/10.1038/s41436-018-0043-3
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Whole Exome Sequencing in Pediatric Neurology PatientsJournal of Child Neurology, 2016
- Availability and payer coverage of BRCA1/2 tests and gene panelsNature Biotechnology, 2015
- The clinical utility of whole‐exome sequencing in the context of rare diseases – the changing tides of medical practiceClinical Genetics, 2015
- Clinical whole exome sequencing in child neurology practiceAnnals of Neurology, 2014
- Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian DisordersThe New England Journal of Medicine, 2013
- Rare-disease genetics in the era of next-generation sequencing: discovery to translationNature Reviews Genetics, 2013
- Health Technology Assessment and Private Payers' Coverage of Personalized MedicineJournal of Oncology Practice, 2011
- Coverage Policy Development for Personalized Medicine: Private Payer Perspectives on Developing Policy for the 21-Gene AssayJournal of Oncology Practice, 2010
- Whole Genome SequencingPublished by Springer Science and Business Media LLC ,2010
- Sequencing technologies — the next generationNature Reviews Genetics, 2009